A felnottkori heveny myeloid leukaemia korszeru kezelése

Translated title of the contribution: Current treatment of acute myeloid leukaemia in adults

Béla Telek, László Rejto, Attila Kiss, Péter Batár, Gyula Reményi, Róbert Szász, Zsófiagnes A. Ujj, Miklós Udvardy

Research output: Contribution to journalArticle

2 Citations (Scopus)


Recent cytogenetical findings and novel molecular biology results of acute myeloid leukaemia have shed new lights of our understanding in the diagnosis and treatment of the disease. Acute myeloid leukaemia is not only represented by the wide variety of morphological and immunophenotypic diversity but also demonstrates cytogenetical and molecular biological heterogeneity of its own. It has an unfavorable prognosis, especially in the elderly. Overall survival of younger patients (<50-60 years) has increased in the past years due to high dose chemotherapy (daunorubicine, cytarabine). But in case of unfavorable prognostic factors (not only cytogenetical but also molecular biological characters of the disease), allogeneic stem cell transplantation is needed for successful overall outcome. Better understanding the biology of acute myeloid leukaemia could establish novel targeted therapies and help us eventually to cure the disease.

Translated title of the contributionCurrent treatment of acute myeloid leukaemia in adults
Original languageHungarian
Pages (from-to)243-249
Number of pages7
JournalOrvosi hetilap
Issue number7
Publication statusPublished - Feb 1 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Current treatment of acute myeloid leukaemia in adults'. Together they form a unique fingerprint.

  • Cite this

    Telek, B., Rejto, L., Kiss, A., Batár, P., Reményi, G., Szász, R., Ujj, Z. A., & Udvardy, M. (2012). A felnottkori heveny myeloid leukaemia korszeru kezelése. Orvosi hetilap, 153(7), 243-249. https://doi.org/10.1556/OH.2012.29304